Other post-transplant maintenance approaches in pediatric acute leukemia include the use of tyrosine kinase inhibitors (TKI) for Philadelphia chromosome-positive ALL, FLT3 inhibitors (e.g., sorafenib and gilteritinib) for FLT3-mutated AML, and donor leukocyte infusions (DLI) to prevent the relapse of AML. The gene discussed is FLT3; the disease is acute lymphoblastic leukemia.